100
Participants
Start Date
March 7, 2007
Primary Completion Date
August 4, 2009
Study Completion Date
June 27, 2013
Omacetaxine mepesuccinate
"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
Teva Investigational Site 350, Budapest
Teva Investigational Site 331, Berlin
Teva Investigational Site 302, The Bronx
Teva Investigational Site 305, Buffalo
Teva Investigational Site 310, Philadelphia
Teva Investigational Site 311, Baltimore
Teva Investigational Site 325, Toulouse
Teva Investigational Site 329, Bordeaux
Teva Investigational Site 390, Bologna
Teva Investigational Site 308, Beech Grove
Teva Investigational Site 322, Lille
Teva Investigational Site 327, Strasbourg
Teva Investigational Site 330, Mannheim
Teva Investigational Site 320, Lyon
Teva Investigational Site 328, Paris
Teva Investigational Site 301, Houston
Teva Investigational Site 321, Le Chesnay
Teva Investigational Site 323, Poitiers
Teva Investigational Site 303, Los Angeles
Teva Investigational Site 314, Seattle
Teva Investigational Site 380, Singapore
Teva Investigational Site 371, Hyderabad
Teva Investigational Site 313, Montreal
Teva Investigational Site 309, Toronto
Teva Investigational Site 324, Nice
Teva Investigational Site 370, Mumbai
Teva Investigational Site 360, Gdansk
Teva Investigational Site 361, Warsaw
Teva Investigational Site 340, London
Collaborators (2)
Cephalon
INDUSTRY
ChemGenex Pharmaceuticals
INDUSTRY
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY